Brokers Offer Predictions for CMPS Q1 Earnings

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for COMPASS Pathways in a research report issued to clients and investors on Tuesday, July 15th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.38) for the quarter. HC Wainwright has a "Buy" rating and a $45.00 price objective on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for COMPASS Pathways' Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.41) EPS and Q4 2026 earnings at ($0.43) EPS.

Several other research firms also recently issued reports on CMPS. Evercore ISI reiterated an "in-line" rating and issued a $6.00 price objective (down previously from $11.00) on shares of COMPASS Pathways in a report on Monday, June 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $12.00 price target on shares of COMPASS Pathways in a report on Tuesday, May 27th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.00.

COMPASS Pathways Trading Up 10.8%

NASDAQ CMPS traded up $0.42 on Wednesday, reaching $4.30. 4,573,064 shares of the company were exchanged, compared to its average volume of 1,306,083. The business's fifty day moving average price is $3.95 and its 200 day moving average price is $3.78. The stock has a market capitalization of $402.31 million, a P/E ratio of -2.16 and a beta of 2.12. The company has a current ratio of 10.18, a quick ratio of 10.18 and a debt-to-equity ratio of 0.11. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.54.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.03.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cerity Partners LLC bought a new position in COMPASS Pathways during the 1st quarter valued at $29,000. GAMMA Investing LLC boosted its position in shares of COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock worth $30,000 after buying an additional 5,003 shares during the period. Ethos Financial Group LLC acquired a new stake in shares of COMPASS Pathways in the first quarter worth $35,000. Flagship Harbor Advisors LLC boosted its position in shares of COMPASS Pathways by 27.7% in the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock worth $41,000 after buying an additional 3,134 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of COMPASS Pathways in the first quarter worth $41,000. 46.19% of the stock is owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.